The Sandhoff Disease (Jatzkewitz-Pilz Syndrome) drugs in development market research report provides comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) by nine companies/universities/institutes. The top development phase for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) is preclinical with six drugs in that stage. The Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline has seven drugs in development by companies and three by universities/ institutes. Some of the companies in the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline products market are: Polaryx Therapeutics, Azafaros and AceLink Therapeutics.
The key targets in the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline products market include Ceramide Glucosyltransferase, Beta-Hexosaminidase Subunit Alpha, and Peroxisome Proliferator Activated Receptor Alpha.
The key mechanisms of action in the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline product include Ceramide Glucosyltransferase Inhibitor with three drugs in Phase III. The Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline products market including Small Molecule, and Cell Therapy.
Sandhoff Disease (Jatzkewitz-Pilz Syndrome) overview
Sandhoff disease is an inherited lipid storage disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. It is caused by a deficiency of the enzyme beta-hexosaminidase. Symptoms include progressive nervous system deterioration, problems initiating and controlling muscles and movement, increased startle reaction to sound, early blindness, seizures, spasticity, and myoclonus. Treatment includes anticonvulsants to control seizures.
For a complete picture of Sandhoff Disease (Jatzkewitz-Pilz Syndrome)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
